Clinically, HER2 overexpression, which is observed in 10–35% of all breast cancers, has been correlated with serious prognostic breast cancer characteristics, as its amplification corresponds with tumor size, lymph node metastasis, a high S-phase fraction, aneuploidy, and a low level of steroid hormone receptors [1,2]. Here, ERBB2 is linked to breast cancer.